Adecatumumab

drugbox-mab


source = Human
target = MT201
CAS_number =
ATC_prefix =
ATC_suffix =
PubChem =
DrugBank =
chemical_formula =
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category =
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Adecatumumab (MT201) is a recombinant human monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326).

Adecatumumab has been used in clinical studies of treatment in prostatecite journal
author=Oberneder R, Weckermann D, Ebner B, "et al"
title=A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients
journal=Eur. J. Cancer
volume=42
issue=15
pages=2530–8
year=2006
month=October
pmid=16930989
doi=10.1016/j.ejca.2006.05.029
url=] and breast cancerscite journal
author=Prang N, Preithner S, Brischwein K, "et al"
title=Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines
journal=Br. J. Cancer
volume=92
issue=2
pages=342–9
year=2005
month=January
pmid=15655555
doi=10.1038/sj.bjc.6602310
url=] .

References